We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urine Liquid Biopsy Test Detects Molecular Evidence of Prostate Cancer

By LabMedica International staff writers
Posted on 29 Mar 2022

A standalone, non-invasive liquid biopsy urine test can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. More...

The miR Sentinel Prostate Cancer Test from miR Scientific, LLC (New York, NY, USA) uses proprietary high-throughput technology based on the interrogation of small noncoding RNAs (sncRNAs) extracted from urinary exosomes. The highly accurate, easy-to-administer miR Sentinel Prostate Cancer Test is powered by the miR Disease Management Platform, the company’s proprietary, non-invasive algorithm-based platform for the effective management of targeted diseases, initially focused on urological cancers. The platform uses precise biologic information interrogation techniques to categorize patients into one of four groups: no cancer, low-risk cancer, intermediate-risk cancer, or high-risk cancer. This gives physicians the ability to clearly determine which patients need treatment and which can be safely and non-invasively monitored, helping avoid harmful and costly overtreatment.

One urine sample is all that’s required for the test to accurately diagnose and classify prostate cancer with 95% sensitivity and specificity, thereby avoiding the standard invasive and inaccurate screening procedures. The test was shown in clinical studies to detect and classify clinically significant prostate cancer with over 90% accuracy. Based on these results, the U.S. Food & Drug Administration has granted the test a Breakthrough Device Designation. When comparing the results of the miR Sentinel Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of clinically significant cancer.

"We believe that the accuracy, accessibility, and non-invasive features of our award-winning technology will impact the lives of millions of men and forever positively evolve the standard of care for urological cancers," said Sam Salman, Chairman and CEO of miR Scientific.

Related Links:
miR Scientific, LLC 


Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Gold Member
Hematology Analyzer
Medonic M32B
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: Development of targeted therapeutics and diagnostics for extrapulmonary tuberculosis at University Hospital Cologne (Photo courtesy of Michael Wodak/Uniklinik Köln)

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.